Marmara University Hospital, Rheumatology Department, Tophanelioglu cad. 13/15, 34662 Altunizade, Istanbul, Turkey.
Rheumatology (Oxford). 2010 Oct;49(10):1889-93. doi: 10.1093/rheumatology/keq171. Epub 2010 Jun 11.
Disease Extent Index-Takayasu (DEI.Tak) is a new index developed for the follow-up of Takayasu's arteritis (TA), assessing only clinical findings without the requirement of imaging. We investigated the effectiveness of DEI.Tak in assessing disease activity and progression by comparing with physician's global assessment (PGA) and active disease criteria defined by Kerr et al.
The initial DEI.Tak forms were filled in for 145 TA patients cross-sectionally to detect the baseline damage and after 29.8 (31) months (n = 105, 144 visits) only by including the new/worsening symptoms within the past 6 months.
At baseline, all patients had a DEI.Tak >0 [mean (s.d.): 7.6 (4.2)]. At this evaluation, 62% of the patients had active, 16.2% had persistent and 21.8% had inactive disease according to the PGA. At follow-up, in 69% of the patients the DEI.Tak score was 0. However, 14% of them were accepted as having active and 17% persistent disease according to PGA. In contrast, 18% with a DEI.Tak ≥ 1 were inactive according to PGA. Patients with active or persistent disease with PGA had higher DEI.Tak compared with inactives [1.3 (1.9), 1 (1.3) vs 0.2 (0.6), respectively; P < 0.001]. According to Kerr's criteria 27% were active. The total agreement between DEI.Tak and Kerr's criteria was 94% (κ = 0.85). Compared with PGA, Kerr's criteria had a total agreement of 74% and DEI.Tak 68%.
During follow-up, most TA patients showed no clinical activity with DEI-Tak. Although the agreement between Kerr's criteria and DEI.Tak seemed very good, using Kerr's criteria instead of DEI.Tak increased the consistency with PGA, which could be explained by the influence of imaging data and acute-phase reactant levels on the physician's decisions.
疾病程度指数- Takayasu(DEI.Tak)是一种新的用于 Takayasu 动脉炎(TA)随访的指标,仅评估临床发现,无需影像学检查。我们通过比较医师总体评估(PGA)和 Kerr 等人定义的活动疾病标准,研究了 DEI.Tak 在评估疾病活动度和进展方面的有效性。
我们对 145 例 TA 患者进行了横断面 DEI.Tak 初始评估,以检测基线损伤,并在 29.8(31)个月后(n=105,144 次就诊)仅纳入过去 6 个月内出现的新/恶化症状。
基线时,所有患者的 DEI.Tak 均大于 0[平均值(标准差):7.6(4.2)]。在此评估中,根据 PGA,62%的患者有活动性疾病,16.2%有持续性疾病,21.8%有无活动性疾病。在随访中,69%的患者的 DEI.Tak 评分为 0。然而,根据 PGA,其中 14%被认为患有活动性疾病,17%患有持续性疾病。相比之下,根据 PGA,18%的 DEI.Tak≥1 的患者无活动性疾病。PGA 为活动性或持续性疾病的患者的 DEI.Tak 高于无活动性疾病的患者[1.3(1.9)、1(1.3)与 0.2(0.6),P<0.001]。根据 Kerr 标准,27%的患者为活动性疾病。DEI.Tak 与 Kerr 标准的总一致性为 94%(κ=0.85)。与 PGA 相比,Kerr 标准的总一致性为 74%,DEI.Tak 为 68%。
在随访过程中,大多数 TA 患者的 DEI-Tak 无临床活动。尽管 Kerr 标准与 DEI.Tak 之间的一致性似乎非常好,但使用 Kerr 标准代替 DEI.Tak 增加了与 PGA 的一致性,这可以用影像学数据和急性期反应物水平对医师决策的影响来解释。